{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:29:39Z","timestamp":1793104179414,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009069.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T00:00:00Z","timestamp":1525824000000}}],"reference-count":341,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009069.pub3","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T21:13:07Z","timestamp":1525813987000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":217,"title":["Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors"],"prefix":"10.1002","volume":"2020","author":[{"given":"Marc","family":"Arbyn","sequence":"first","affiliation":[{"name":"Sciensano; Unit of Cancer Epidemiology, Belgian Cancer Centre; Juliette Wytsmanstreet 14 Brussels Belgium B-1050"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Xu","sequence":"additional","affiliation":[{"name":"Sciensano; Unit of Cancer Epidemiology, Belgian Cancer Centre; Juliette Wytsmanstreet 14 Brussels Belgium B-1050"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Simoens","sequence":"additional","affiliation":[{"name":"University of Antwerp; Laboratory of Cell Biology and Histology; Groenenborgerlaan 171 Antwerp Belgium B-2020"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre PL","family":"Martin-Hirsch","sequence":"additional","affiliation":[{"name":"Royal Preston Hospital, Lancashire Teaching Hospital NHS Trust; Gynaecological Oncology Unit; Sharoe Green Lane Fullwood Preston Lancashire UK PR2 9HT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,9]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD009069.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/infdis\/jis619","article-title":"Safety and immunogenicity of human papillomavirus-16\/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women","volume":"207","author":"Sow","year":"2013","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/21645515.2015.1008877","article-title":"Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa","volume":"11","author":"Mugo","year":"2015","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.4161\/hv.28702","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years","volume":"10","author":"Zhu","year":"2014","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.4161\/hv.28702","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years","volume":"10","author":"Zhu","year":"2014","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"11","key":"10.1002\/14651858.CD009069.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/ijc.28897","article-title":"Efficacy, immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial","volume":"135","author":"Zhu","year":"2014","journal-title":"International Journal of Cancer"},{"issue":"2045-7634 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/cam4.869","article-title":"Efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial","volume":"6","author":"Zhu","year":"2017","journal-title":"Cancer Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009069.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jadohealth.2009.11.205","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women","volume":"46","author":"Garcia-Sicilia","year":"2010","journal-title":"Journal of Adolescent Health"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jadohealth.2011.10.009","article-title":"Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16\/18AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls","volume":"50","author":"Pedersen","year":"2012","journal-title":"Journal of Adolescent Health"},{"issue":"49","key":"10.1002\/14651858.CD009069.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"9276","DOI":"10.1016\/j.vaccine.2011.08.037","article-title":"Co-administration of human papillomavirus-16\/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls","volume":"29","author":"Schmeink","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","article-title":"Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: A community-based randomized clinical trial in Guanacaste, Costa Rica","volume":"1","author":"Herrero","year":"2011","journal-title":"Cancer Discovery"},{"issue":"39","key":"10.1002\/14651858.CD009069.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1016\/j.vaccine.2014.06.038","article-title":"Efficacy of the HPV-16\/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16\/18 vaccine trial","volume":"32","author":"Hildesheim","year":"2014","journal-title":"Vaccine"},{"issue":"9","key":"10.1002\/14651858.CD009069.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(11)70213-3","article-title":"Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV 16\/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial","volume":"12","author":"Kreimer","year":"2011","journal-title":"Lancet Oncology"},{"issue":"19","key":"10.1002\/14651858.CD009069.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"Journal of the National Cancer Institute"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/aje\/kwu168","article-title":"Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates","volume":"180","author":"Lang Kuhs","year":"2014","journal-title":"American Journal of Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16 to 26 years","volume":"199","author":"Brown","year":"2009","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"Dillner","year":"2010","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD009069.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prevention Research"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"Journal of the National Cancer Institute"},{"issue":"10","key":"10.1002\/14651858.CD009069.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Human Vaccines"},{"issue":"10","key":"10.1002\/14651858.CD009069.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1086\/522864","article-title":"Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection","volume":"196","author":"The FUTURE II study group","year":"2007","journal-title":"Journal of Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16 to 26 years","volume":"199","author":"Wheeler","year":"2009","journal-title":"Journal of Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 to 45 years of age","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"British Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/AOG.0b013e3181c2ca21","article-title":"Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6\/11\/16\/18vaccine: a combined analysis of five randomized controlled trials","volume":"114","author":"Garland","year":"2009","journal-title":"Obstetrics and Gynecology"},{"issue":"9679","key":"10.1002\/14651858.CD009069.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial","volume":"373","author":"Munoz","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/AOG.0b013e3181c2ca21","article-title":"Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6\/11\/16\/18vaccine: a combined analysis of five randomized controlled trials","volume":"114","author":"Garland","year":"2009","journal-title":"Obstetrics and Gynecology"},{"issue":"19","key":"10.1002\/14651858.CD009069.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"The FUTURE II study group","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/AOG.0b013e3181c2ca21","article-title":"Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6\/11\/16\/18vaccine: a combined analysis of five randomized controlled trials","volume":"114","author":"Garland","year":"2009","journal-title":"Obstetrics and Gynecology"},{"issue":"19","key":"10.1002\/14651858.CD009069.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"1024-2708 (Prin","key":"10.1002\/14651858.CD009069.pub3-BIB0029|cit29","first-page":"171","article-title":"Human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong","volume":"16","author":"Ngan","year":"2010","journal-title":"Hong Kong Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jadohealth.2010.02.006","article-title":"Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls","volume":"46","author":"Medina","year":"2010","journal-title":"Journal of Adolescent Health"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1447-0756.2009.01167.x","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women","volume":"36","author":"Bhatla","year":"2010","journal-title":"Journal of Obstetrics and Gynaecology Research"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/IGC.0b013e3181d373a5","article-title":"Efficacy of human papillomavirus 16\/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial","volume":"20","author":"Konno","year":"2010","journal-title":"International Journal of Gynecological Cancer"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/IGC.0b013e3181da2128","article-title":"Efficacy of human papillomavirus type 16\/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial","volume":"20","author":"Konno","year":"2010","journal-title":"International Journal of Gynecological Cancer"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.4161\/hv.28712","article-title":"Efficacy of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women","volume":"10","author":"Konno","year":"2014","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"4","key":"10.1002\/14651858.CD009069.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/cas.12106","article-title":"Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18 to 26 years","volume":"104","author":"Yoshikawa","year":"2013","journal-title":"Cancer Science"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1525-1438.2007.01123.x","article-title":"Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects","volume":"18","author":"Kang","year":"2008","journal-title":"International Journal of Gynecological Cancer"},{"issue":"8","key":"10.1002\/14651858.CD009069.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3346\/jkms.2010.25.8.1197","article-title":"Vaccination with a human papillomavirus (HPV)-16\/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years","volume":"25","author":"Kim","year":"2010","journal-title":"Journal of Korean Medical Science"},{"issue":"2","key":"10.1002\/14651858.CD009069.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3802\/jgo.2011.22.2.67","article-title":"Human papillomavirus 16\/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15 to 25 years old healthy Korean women","volume":"22","author":"Kim","year":"2011","journal-title":"Journal of Gynecologic Oncology"},{"issue":"0300-5283 (Prin","key":"10.1002\/14651858.CD009069.pub3-BIB0039|cit39","first-page":"2","article-title":"Immunogenicity and safety of the AS04-adjuvanted human papillomavirus-16\/18 cervical cancer vaccine in Malaysian women aged 18 to 35 years: a randomized controlled trial","volume":"69","author":"Lim","year":"2014","journal-title":"Medical Journal of Malaysia"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"c712","DOI":"10.1136\/bmj.c712","article-title":"Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials","volume":"340","author":"Wacholder","year":"2010","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 ASO4-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncology"},{"issue":"9580","key":"10.1002\/14651858.CD009069.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/ijc.26362","article-title":"Efficacy of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV-16\/18","volume":"131","author":"Szarewski","year":"2011","journal-title":"International Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV-types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2011","journal-title":"Lancet Oncology"},{"issue":"21","key":"10.1002\/14651858.CD009069.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial","volume":"107","author":"Mao","year":"2006","journal-title":"Obstetrics and Gynecology"},{"issue":"41","key":"10.1002\/14651858.CD009069.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1016\/j.vaccine.2009.07.027","article-title":"Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine","volume":"27","author":"Rowhani-Rahbar","year":"2009","journal-title":"Vaccine"},{"issue":"38","key":"10.1002\/14651858.CD009069.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1016\/j.vaccine.2010.07.007","article-title":"Sustained efficacy and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women","volume":"28","author":"Carvalho","year":"2010","journal-title":"Vaccine"},{"issue":"9447","key":"10.1002\/14651858.CD009069.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"9518","key":"10.1002\/14651858.CD009069.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD009069.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination","volume":"10","author":"Naud","year":"2014","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 ASO4-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years","volume":"374","author":"The GlaxoSmithKline Vaccine HPV-007 Study Group","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD009069.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Human Vaccines"},{"issue":"27","key":"10.1002\/14651858.CD009069.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncology"},{"issue":"11","key":"10.1002\/14651858.CD009069.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"British Journal of Cancer"},{"issue":"9961","key":"10.1002\/14651858.CD009069.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(14)60920-X","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"384","author":"Skinner","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD009069.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1154\u201368","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"16","author":"Wheeler","year":"2016","journal-title":"Lancet Infectious Diseases"},{"issue":"1099-557 (Elect","key":"10.1002\/14651858.CD009069.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/pds.3554","article-title":"Pooled analysis of large and long-term safety data from the human papillomavirus-16\/18-AS04-adjuvanted vaccine clinical trial programme","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"1873-2518 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.vaccine.2010.02.045","article-title":"Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines","volume":"28","author":"Arguedas","year":"2010","journal-title":"Vaccine"},{"issue":"23-24","key":"10.1002\/14651858.CD009069.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1016\/j.vaccine.2004.02.020","article-title":"A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine","volume":"22","author":"Ault","year":"2004","journal-title":"Vaccine"},{"issue":"9576","key":"10.1002\/14651858.CD009069.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD009069.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4103\/2278-330X.119877","article-title":"Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and national programs","volume":"2","author":"Basu","year":"2013","journal-title":"South Asian Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"djv302","DOI":"10.1093\/jnci\/djv302","article-title":"Multisite HPV16\/18 vaccine efficacy against cervical, anal, and oral HPV infection","volume":"108","author":"Beachler","year":"2016","journal-title":"Journal of the National Cancer Institute"},{"issue":"21-22","key":"10.1002\/14651858.CD009069.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1016\/j.vaccine.2003.11.059","article-title":"Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine","volume":"22","author":"Brown","year":"2004","journal-title":"Vaccine"},{"issue":"1471-2458 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1186\/1471-2458-14-867","article-title":"HPV catch-up vaccination of young women: a systematic review and meta-analysis","volume":"14","author":"Couto","year":"2014","journal-title":"BMC Public Health"},{"issue":"1873-2518 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1016\/j.vaccine.2017.03.096","article-title":"Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis","volume":"35","author":"D'Addario","year":"2017","journal-title":"Vaccine"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/07359683.2013.814486","article-title":"Preventive innovation: an Australian case study on HPV vaccination","volume":"30","author":"D'Souza","year":"2013","journal-title":"Health Marketing Quartely"},{"issue":"8","key":"10.1002\/14651858.CD009069.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.4161\/hv.24904","article-title":"HPV vaccination coverage among women aged 18-20 years in Germany three years after recommendation of HPV vaccination for adolescent girls: results from a cross-sectional survey","volume":"9","author":"Delere","year":"2013","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"48","key":"10.1002\/14651858.CD009069.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1016\/j.vaccine.2013.09.032","article-title":"Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study","volume":"31","author":"Denny","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4161\/hv.5.5.7211","article-title":"Safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials","volume":"5","author":"Descamps","year":"2009","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"1179-411 (Elect","key":"10.1002\/14651858.CD009069.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2147\/IJWH.S50365","article-title":"Long-term efficacy and safety of human papillomavirus vaccination","volume":"6","author":"Vincenzo","year":"2014","journal-title":"International Journal of Womens Health"},{"issue":"17","key":"10.1002\/14651858.CD009069.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"issue":"47","key":"10.1002\/14651858.CD009069.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1016\/j.vaccine.2011.09.021","article-title":"Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera","volume":"29","author":"Draper","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"e61825","DOI":"10.1371\/journal.pone.0061825","article-title":"A randomized, observer-blinded immunogenicity trial of cervarix((R)) and gardasil((R)) human papillomavirus vaccines in 12-15 year old girls","volume":"8","author":"Draper","year":"2013","journal-title":"PLOS One"},{"issue":"10","key":"10.1002\/14651858.CD009069.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18 to 45 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"12","key":"10.1002\/14651858.CD009069.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4161\/hv.7.12.18281","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV) 16\/18 vaccine and HPV-6\/11\/16\/18 vaccine: Follow-up from months 12 to 24 in a Phase III randomized study of healthy women aged 18 to 45 years","volume":"7","author":"Einstein","year":"2011","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"0022-1899, 10","key":"10.1002\/14651858.CD009069.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1086\/320190","article-title":"A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers","volume":"183","author":"Evans","year":"2001","journal-title":"Journal of Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0080|cit80","first-page":"1","article-title":"Safety of the HPV bivalent and quadrivalent vaccines during pregnancy","volume":"45","author":"Forinash","year":"2011","journal-title":"Annals of Pharmacotherapy"},{"issue":"1097-0215 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/ijc.30391","article-title":"Prior human papillomavirus-16\/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial","volume":"139","author":"Garland","year":"2016","journal-title":"International Journal of Cancer"},{"issue":"8","key":"10.1002\/14651858.CD009069.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1086\/521679","article-title":"Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine","volume":"196","author":"Giuliano","year":"2007","journal-title":"Journal of Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"New England Journal of Medcine"},{"issue":"1873-2518 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1016\/j.vaccine.2015.08.072","article-title":"Immunogenicity and safety of Gardasil among mid-adult aged men (27 to 45 years) The MAM Study","volume":"33","author":"Giuliano","year":"2015","journal-title":"Vaccine"},{"issue":"37","key":"10.1002\/14651858.CD009069.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1016\/j.vaccine.2013.06.057","article-title":"Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males","volume":"31","author":"Goldstone","year":"2013","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/14651858.CD009069.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnci\/93.4.284","article-title":"Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine","volume":"93","author":"Harro","year":"2001","journal-title":"Journal of the National Cancer Institute"},{"issue":"11","key":"10.1002\/14651858.CD009069.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/ijc.25940","article-title":"Impact of an HPV6\/11\/16\/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16\/18 infection","volume":"129","author":"Haupt","year":"2011","journal-title":"International Journal of Cancer"},{"issue":"1468-2060 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1136\/annrheumdis-2013-203429","article-title":"Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study","volume":"73","author":"Heijstek","year":"2014","journal-title":"Annals of the RheumaticDiseases"},{"issue":"2164-554X (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/21645515.2015.1058458","article-title":"Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes","volume":"12","author":"Hernandez-Avila","year":"2016","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"e68329","DOI":"10.1371\/journal.pone.0068329","article-title":"Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica","volume":"8","author":"Herrero","year":"2013","journal-title":"PLOS One"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/CVI.05208-11","article-title":"The immunogenicity of quadrivalent HPV (type 6\/11\/16\/18) vaccine in males aged 16 to 26","volume":"19","author":"Hillman","year":"2011","journal-title":"Clinical and Vaccine Immunology"},{"issue":"9574","key":"10.1002\/14651858.CD009069.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/cid\/cit319","article-title":"Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women","volume":"57","author":"Kahn","year":"2013","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD009069.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2013.04.050","article-title":"Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?","volume":"130","author":"Kang","year":"2013","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/jjco\/hyr173","article-title":"Safety and immunogenicity profile of human papillomavirus-16\/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh","volume":"42","author":"Khatun","year":"2012","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"1940-6215 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prevention Research (Philadelphia, Pa.)"},{"issue":"3 1460-2105 (El","key":"10.1002\/14651858.CD009069.pub3-BIB0098|cit98","first-page":"1-4 0027-8874 (","article-title":"The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents","volume":"107","author":"Kreimer","year":"2015","journal-title":"Journal of the National Cancer Institute"},{"issue":"8","key":"10.1002\/14651858.CD009069.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/infdis\/jit363","article-title":"Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose","volume":"208","author":"Lamontagne","year":"2013","journal-title":"Journal of Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD009069.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiu357","article-title":"Reduced prevalence of vulvar HPV16\/18 infection among women who received the HPV16\/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial","volume":"210","author":"Lang Kuhs","year":"2014","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.vaccine.2013.11.059","article-title":"Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16\/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months","volume":"32","author":"Lazcano-Ponce","year":"2014","journal-title":"Vaccine"},{"issue":"2164-554X (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1080\/21645515.2016.1183847","article-title":"Safety of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial","volume":"12","author":"Lehtinen","year":"2016","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"9","key":"10.1002\/14651858.CD009069.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1128\/CVI.00539-10","article-title":"Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16\/18 AS04-adjuvanted cervical cancer vaccine","volume":"18","author":"Leroux-Roels","year":"2011","journal-title":"Clinical Vaccine Immunology"},{"issue":"2164-554X (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1080\/21645515.2015.1050570","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial","volume":"11","author":"Leung","year":"2015","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"28","key":"10.1002\/14651858.CD009069.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1016\/j.vaccine.2012.02.079","article-title":"Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females","volume":"30","author":"Li","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.vaccine.2013.11.098","article-title":"Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males","volume":"32","author":"Lin","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2334-11-13","article-title":"Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis","volume":"11","author":"Lu","year":"2011","journal-title":"BMC Infectious Disease"},{"issue":"12","key":"10.1002\/14651858.CD009069.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"e83431","DOI":"10.1371\/journal.pone.0083431","article-title":"Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil in adult women","volume":"8","author":"Luna","year":"2013","journal-title":"PLOS One"},{"issue":"10","key":"10.1002\/14651858.CD009069.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malagon","year":"2012","journal-title":"Lancet Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/11205060-000000000-00000","article-title":"Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil\u00ae) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women","volume":"25","author":"McCormack","year":"2011","journal-title":"BioDrugs"},{"issue":"4","key":"10.1002\/14651858.CD009069.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/11206830-000000000-00000","article-title":"Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix\u00ae)","volume":"25","author":"McKeage","year":"2011","journal-title":"BioDrugs"},{"issue":"40","key":"10.1002\/14651858.CD009069.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1016\/j.vaccine.2016.08.016","article-title":"HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine","volume":"34","author":"Money","year":"2016","journal-title":"Vaccine"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4161\/hv.7.7.15579","article-title":"Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults","volume":"7","author":"Moreira","year":"2011","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"1750-9378 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13027-015-0012-2","article-title":"Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy","volume":"10","author":"Nakalembe","year":"2015","journal-title":"Infectious Agents and Cancer"},{"issue":"34","key":"10.1002\/14651858.CD009069.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1016\/j.vaccine.2013.06.034","article-title":"A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years","volume":"31","author":"Nelson","year":"2013","journal-title":"Vaccine"},{"issue":"14","key":"10.1002\/14651858.CD009069.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jama.2011.407","article-title":"Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial","volume":"305","author":"Neuzil","year":"2011","journal-title":"JAMA"},{"issue":"1554-8619 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Human Vaccines"},{"issue":"17","key":"10.1002\/14651858.CD009069.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant","volume":"40","author":"Pedersen","year":"2007","journal-title":"Journal of Adolescent Health"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/ijc.23260","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women","volume":"122","author":"Perez","year":"2008","journal-title":"International Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jadohealth.2008.10.002","article-title":"Immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years","volume":"44","author":"Petaja","year":"2009","journal-title":"Journal of Adolescent Health"},{"issue":"9","key":"10.1002\/14651858.CD009069.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ijc.25887","article-title":"Long-term persistence of systemic and mucosal immune response to HPV-16\/18 AS04-adjuvanted vaccine in preteen\/adolescent girls and young women","volume":"129","author":"Petaja","year":"2011","journal-title":"International Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"601","DOI":"10.4065\/80.5.601","article-title":"Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial","volume":"80","author":"Poland","year":"2005","journal-title":"Mayo Clinic Proceedings"},{"issue":"4","key":"10.1002\/14651858.CD009069.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/infdis\/jiw036","article-title":"Randomized open trial comparing 2-dose regimens of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years","volume":"214","author":"Puthanakit","year":"2016","journal-title":"Journal of Infectious Diseases"},{"issue":"2044-6055 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"e011371","DOI":"10.1136\/bmjopen-2016-011371","article-title":"Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naive women: results from the control arm of a phase II HPV-16\/18 vaccine trial","volume":"6","author":"Ramanakumar","year":"2016","journal-title":"BMJ Open."},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/sextrans-2011-050234","article-title":"The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme","volume":"87","author":"Read","year":"2011","journal-title":"Sexually Transmitted Infections"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1542\/peds.2009-2336","article-title":"Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel","volume":"125","author":"Reisinger","year":"2010","journal-title":"Pediatrics"},{"issue":"2164-554X (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/21645515.2015.1065363","article-title":"Sustained immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study","volume":"12","author":"Romanowski","year":"2016","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcv.2011.12.009","article-title":"Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine","volume":"53","author":"Rowhani-Rahbar","year":"2012","journal-title":"Journal of Clinical Virology"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.4161\/hv.24340","article-title":"Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial","volume":"9","author":"Safaeian","year":"2013","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD009069.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ygyno.2008.05.036","article-title":"Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16\/18 vaccine: improving upon nature","volume":"110","author":"Schwarz","year":"2008","journal-title":"Gynecologic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD009069.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.vaccine.2008.10.088","article-title":"Immunogenicity and tolerability of an HPV-16\/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years","volume":"27","author":"Schwarz","year":"2009","journal-title":"Vaccine"},{"issue":"12","key":"10.1002\/14651858.CD009069.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4161\/hv.6.12.13399","article-title":"Correlation between levels of human papillomavirus (HPV) 16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16\/18 AS04-adjuvanted vaccine","volume":"6","author":"Schwarz","year":"2010","journal-title":"Human Vaccine & Immunotherapeutics"},{"issue":"9","key":"10.1002\/14651858.CD009069.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"958","DOI":"10.4161\/hv.7.9.15999","article-title":"Persistence of immune response to HPV-16\/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years","volume":"7","author":"Schwarz","year":"2011","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"1532-0987 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1097\/INF.0000000000000460","article-title":"Long-term immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial","volume":"33","author":"Schwarz","year":"2014","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"9767","key":"10.1002\/14651858.CD009069.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(11)60270-5","article-title":"Human papillomavirus vaccine trials in India","volume":"377","author":"Sengupta","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0138|cit138","first-page":"248","article-title":"Human papilloma virus vaccines and current controversy","volume":"48","author":"Singhal","year":"2011","journal-title":"Indian Pediatrics"},{"issue":"1744-8395 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1586\/14760584.2016.1124763","article-title":"Human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases","volume":"15","author":"Skinner","year":"2016","journal-title":"Expert Review of Vaccines"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/ebm1066","article-title":"Quadrivalent HPV vaccine administered to women who became pregnant during trials did not appear to adversely affect pregnancy outcome; however, use during pregnancy is not recommended","volume":"15","author":"Smith-McCune","year":"2010","journal-title":"Evidence Based Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009069.pub3-BIB0141|cit141","first-page":"73","article-title":"HPV vaccine trials and sleeping watchdogs","volume":"8","author":"Srinivasan","year":"2011","journal-title":"Indian Journal of Medical Ethics"},{"issue":"8","key":"10.1002\/14651858.CD009069.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/infdis\/jit657","article-title":"Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial","volume":"209","author":"Toft","year":"2014","journal-title":"Journal of Infectious Diseases"},{"issue":"28","key":"10.1002\/14651858.CD009069.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1016\/j.vaccine.2011.04.050","article-title":"Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16\/18 vaccine in the Netherlands","volume":"29","author":"Klooster","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/14651858.CD009069.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/INF.0b013e3181c177fb","article-title":"An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6\/11\/16\/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age","volume":"29","author":"Vesikari","year":"2010","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"0264-410X (Prin","key":"10.1002\/14651858.CD009069.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.vaccine.2007.11.043","article-title":"Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6\/11\/16\/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines","volume":"26","author":"Wheeler","year":"2008","journal-title":"Vaccine"},{"issue":"12","key":"10.1002\/14651858.CD009069.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1097\/INF.0b013e31822d28df","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and\/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial","volume":"30","author":"Wheeler","year":"2011","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"7-8","key":"10.1002\/14651858.CD009069.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1345\/aph.1P017","article-title":"The prophylactic role for the human papillomavirus quadrivalent vaccine in males","volume":"44","author":"Yancey","year":"2010","journal-title":"Annals of Pharmacotherapy"},{"issue":"8","key":"10.1002\/14651858.CD009069.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5732\/cjc.010.10564","article-title":"Safety and immunogenicity of human papillomavirus-16\/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial","volume":"30","author":"Zhu","year":"2011","journal-title":"Chinese Journal of Cancer"},{"issue":"8","key":"10.1002\/14651858.CD009069.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1089\/jwh.2009.1753","article-title":"Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women","volume":"19","author":"Zimmerman","year":"2010","journal-title":"Journal of Women's Health"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.vaccine.2017.01.076","article-title":"No increased risk of Guillain-Barr\u00e9 syndrome after human papilloma virus vaccine: A self-controlled case-series study in England","volume":"35","author":"Andrews","year":"2017","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0151|cit151","first-page":"1","article-title":"Risk of auto-immune diseases after vaccination against HPV: a pharmacoepidemiological study","volume":"Website accesse","author":"ANSM\/SANTE","year":"September 2015","journal-title":"http:\/\/ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Vaccination-contre-les-infections-a-HPV-et-risque-de-maladies-auto-immunes-une-etude-Cnamts-ANSM-rassurante-Point-d-information"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcv.2006.12.009","article-title":"Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening","volume":"38","author":"Arbyn","year":"2007","journal-title":"Journal of Clinical Virology"},{"issue":"15","key":"10.1002\/14651858.CD009069.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1016\/j.ejca.2009.07.016","article-title":"The challenges for organising cervical screening programmes in the 15 old member states of the European Union","volume":"45","author":"Arbyn","year":"2009","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/172460081002500301","article-title":"Cervical cytology biobanking in Europe","volume":"25","author":"Arbyn","year":"2010","journal-title":"Internatonal Journal of Biological Markers"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1093\/annonc\/mdr015","article-title":"Worldwide burden of cervical cancer in 2008","volume":"22","author":"Arbyn","year":"2011","journal-title":"Annals of Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD009069.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"F88","DOI":"10.1016\/j.vaccine.2012.06.095","article-title":"Evidence regarding HPV testing in secondary prevention of cervical cancer","volume":"30","author":"Arbyn","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/14651858.CD009069.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/path.4424","article-title":"Are 20 human papillomavirus types causing cervical cancer?","volume":"234","author":"Arbyn","year":"2014","journal-title":"Journal of Pathology"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.canep.2015.12.011","article-title":"Surveillance of effects of HPV vaccination in Belgium","volume":"41","author":"Arbyn","year":"2016","journal-title":"Cancer Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD009069.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S1470-2045(17)30700-3","article-title":"Incomplete excision of cervical pre-cancer as predictor of treatment failure: a systematic review and meta-analysis","volume":"18","author":"Arbyn","year":"2017","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"f5906","DOI":"10.1136\/bmj.f5906","article-title":"Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study","volume":"347","author":"Arnheim-Dahlstrom","year":"2013","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"dtj460","DOI":"10.1093\/jnci\/djt460","article-title":"Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women","volume":"106","author":"Baldur-Felskov","year":"2014","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1016\/j.vaccine.2015.07.024","article-title":"Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16\/18 AS04-adjuvanted vaccine in the United Kingdom","volume":"33","author":"Baril","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1447-0756.2009.01167.x","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women","volume":"36","author":"Bhatla","year":"2010","journal-title":"Journal of Obstetrics and Gynaecology Research"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"Journal of Clinical Pathology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD009069.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1016\/j.vaccine.2008.05.064","article-title":"Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia","volume":"26","author":"Bosch","year":"2008","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrclinonc.2015.146","article-title":"HPV-FASTER: broadening the scope for prevention of HPV-related cancer","volume":"13","author":"Bosch","year":"2016","journal-title":"Nature Reviews, Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD009069.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens - Part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncology"},{"issue":"9","key":"10.1002\/14651858.CD009069.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1158\/1055-9965.EPI-05-0231","article-title":"Incidence trends of adenocarcinoma of the cervix in 13 European countries","volume":"14","author":"Bray","year":"2005","journal-title":"Cancer Epidemiology, Biomarkers and Prevention"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1055-9965.EPI-04-0569","article-title":"Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening","volume":"14","author":"Bray","year":"2005","journal-title":"Cancer Epidemiology, Biomarkers and Prevention"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1128\/jvi.69.6.3959-3963.1995","article-title":"Immunization with virus like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection","volume":"69","author":"Breitburd","year":"1995","journal-title":"Journal of Virology"},{"issue":"1474-547X (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pvr.2015.05.005","article-title":"Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia","volume":"1","author":"Brotherton","year":"2015","journal-title":"Papillomavirus Research"},{"issue":"9","key":"10.1002\/14651858.CD009069.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1086\/323645","article-title":"Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer","volume":"184","author":"Brown","year":"2001","journal-title":"Journal of Infectious Diseases"},{"issue":"1-2","key":"10.1002\/14651858.CD009069.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.virol.2013.07.015","article-title":"A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types","volume":"445","author":"Bzhalava","year":"2013","journal-title":"Virology"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0175|cit175","unstructured":"Cancer Researck UK Cervical cancer incidence statistics http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/cervical-cancer\/incidence Accessed Jan 2018"},{"issue":"1460-2105 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jnci\/djj067","article-title":"Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention","volume":"98","author":"Castellsagu\u00e9","year":"2006","journal-title":"Journal of the National Cancer Institute"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"h5496","DOI":"10.1136\/bmj.h5496","article-title":"Clinical importance cannot be ruled out using mean difference alone","volume":"351","author":"Cates","year":"2015","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0179|cit179","unstructured":"Sukumaran L Advisory Committee on Immunization Practices - Immunization Safety Office - Centers for Disease Control and Prevention (CDC Atlanta) Human Papillomavirus Vaccine Safety Update http:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2015-10\/hpv-04-sukumaran.pdf"},{"issue":"2","key":"10.1002\/14651858.CD009069.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2796.2011.02467.x","article-title":"Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine","volume":"271","author":"Chao","year":"2012","journal-title":"Journal of Internal Medicine"},{"issue":"1470-2045, 4","key":"10.1002\/14651858.CD009069.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1470-2045(05)70086-3","article-title":"Carcinogenicity of human papillomaviruses","volume":"6","author":"Cogliano","year":"2005","journal-title":"Lancet Oncology"},{"issue":"g1458","key":"10.1002\/14651858.CD009069.pub3-BIB0182|cit182","first-page":"1","article-title":"Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia","volume":"348","author":"Crowe","year":"2014","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD009069.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/bjc.2016.97","article-title":"mpact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis","volume":"114","author":"Cuschieri","year":"2016","journal-title":"British Journal of Cancer"},{"issue":"1873-233X (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/AOG.0b013e3181c2a122","article-title":"Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6\/11\/16\/18 vaccine","volume":"114","author":"Dana","year":"2009","journal-title":"Obstetrics and Gynaecology"},{"issue":"38","key":"10.1002\/14651858.CD009069.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1016\/j.vaccine.2010.07.007","article-title":"Sustained efficacy and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women","volume":"28","author":"Carvalho","year":"2010","journal-title":"Vaccine"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","article-title":"Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis","volume":"7","author":"Sanjose","year":"2007","journal-title":"Lancet Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD009069.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"Sanjose","year":"2010","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0188|cit188","doi-asserted-by":"crossref","DOI":"10.1002\/9780470693926.ch15","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","volume-title":"In: Egger M, Davey Smith G, Altman DG (eds).\u00a0 Systematic Reviews in Health Care: Meta-Analysis in Context (2nd edition)","author":"Deeks","year":"2001"},{"issue":"35-36","key":"10.1002\/14651858.CD009069.pub3-BIB0189|cit189","first-page":"584","article-title":"The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis","volume":"111","author":"Delere","year":"2014","journal-title":"Deutsches Arzteblatt International"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2249.2010.04268.x","article-title":"Monitoring of human papillomavirus vaccination","volume":"163","author":"Dillner","year":"2011","journal-title":"Clinical & Experimental Immunology"},{"issue":"43","key":"10.1002\/14651858.CD009069.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1016\/j.vaccine.2013.08.024","article-title":"Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK","volume":"31","author":"Donegan","year":"2013","journal-title":"Vaccine"},{"issue":"1474-4457 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","article-title":"Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data","volume":"11","author":"Donovan","year":"2011","journal-title":"Lancet Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0195|cit195","unstructured":"European Medicines Agency HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/HPV_vaccines_20\/European_Commission_final_decision\/WC500196773.pdf"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0196|cit196","first-page":"1","article-title":"EMEA\/H\/C\/000721-Cervarix-EPAR summary for the public 2014","volume":"Accessed 10-12-","author":"European Medicines Agency","year":"Februrary 2014","journal-title":"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000721\/WC500024634.pdf."},{"key":"10.1002\/14651858.CD009069.pub3-BIB0197|cit197","first-page":"1","article-title":"EMEA\/H\/C\/000703-Gardasil-EPAR summary for the public 2014","volume":"Accessed 10-12-","author":"European Medicines Agency","year":"August 2014","journal-title":"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000703\/WC500021146.pdf"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0198|cit198","unstructured":"EMEA Review concludes evidence does not support that HPV vaccines cause CRPS or POTS http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2015\/11\/news_detail_002429.jsp&mid=WC0b01ac058004d5c1"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30 Suppl 5","author":"Forman","year":"2012","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri1260","article-title":"Prevention of cervical cancer through papillomavirus vaccination","volume":"4","author":"Frazer","year":"2004","journal-title":"Nature Reviews Immunology"},{"issue":"19","key":"10.1002\/14651858.CD009069.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"The FUTURE II study group","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1473-3099(03)00720-5","article-title":"Papillomavirus vaccines in clinical trials","volume":"3","author":"Galloway","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD009069.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jadohealth.2009.11.205","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women","volume":"46","author":"Garcia-Sicilia","year":"2010","journal-title":"Journal of Adolescent Health"},{"issue":"19","key":"10.1002\/14651858.CD009069.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"1128","key":"10.1002\/14651858.CD009069.pub3-BIB0207|cit207","first-page":"1","article-title":"An evaluation of non-inferiority in antibody response to human papillomavirus (HPV) 16 in subjects vaccinated with monovalent (HPV 16) and quadrivalent (HPV 6, 11, 16, 18) L1 virus like particle vaccines","volume":"10","author":"Garland","year":"2007","journal-title":"Clinical and Vaccine Immunology"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/AOG.0b013e3181c2ca21","article-title":"Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6\/11\/16\/18 Vaccine: a combined analysis of five randomized controlled trials","volume":"114","author":"Garland","year":"2009","journal-title":"Obstetrics and Gynecology"},{"issue":"43","key":"10.1002\/14651858.CD009069.pub3-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.1016\/j.vaccine.2017.09.009","article-title":"Risk of Guillain-Barr\u00e9 syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink","volume":"35","author":"Gee","year":"2017","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/1741-7015-11-227","article-title":"mpact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study","volume":"11","author":"Gertig","year":"2013","journal-title":"BMC Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/exmp.1999.2298","article-title":"Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus","volume":"68","author":"Ghim","year":"2000","journal-title":"Experimental and Molecular Pathology"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.vaccine.2015.04.014","article-title":"Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine","volume":"33","author":"Goss","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/14651858.CD009069.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joim.12155","article-title":"Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects","volume":"275","author":"Grimaldi-Bensouda","year":"2014","journal-title":"Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaut.2017.01.005","article-title":"Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance","volume":"79","author":"Grimaldi-Bensouda","year":"2017","journal-title":"Journal of Autoimmunity"},{"issue":"7650","key":"10.1002\/14651858.CD009069.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD009069.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1536867X0900900202","article-title":"Updated tests for small-study effects in meta-analyses","volume":"9","author":"Harbord","year":"2009","journal-title":"Stata Journal"},{"issue":"9447","key":"10.1002\/14651858.CD009069.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"9518","key":"10.1002\/14651858.CD009069.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD009069.pub3-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1586\/erv.09.123","article-title":"Currently approved prophylactic HPV vaccines","volume":"8","author":"Harper","year":"2009","journal-title":"Expert Review of Vaccines"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","article-title":"Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: A community-based randomized clinical trial in guanacaste, Costa Rica","volume":"1","author":"Herrero","year":"2011","journal-title":"Cancer Discovery"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0223|cit223","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"39","key":"10.1002\/14651858.CD009069.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1016\/j.vaccine.2014.06.038","article-title":"Efficacy of the HPV-16\/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16\/18 vaccine trial","volume":"32","author":"Hildesheim","year":"2014","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJM199802123380703","article-title":"Natural history of cervicovaginal papillomavirus infection in young women","volume":"338","author":"Ho","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/jamapediatrics.2015.3926","article-title":"Human papillomavirus vaccination and cervical cytology outcomes among urban low-income minority females","volume":"170","author":"Hofstetter","year":"2016","journal-title":"JAMA Pediatrics"},{"issue":"10108","key":"10.1002\/14651858.CD009069.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0229|cit229","first-page":"1","article-title":"Cervix Cancer Screening","volume-title":"IARC Handbooks of Cancer Prevention","volume":"10","author":"(Day","year":"2005"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0230|cit230","first-page":"1","volume-title":"IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 90: Human Papillomaviruses","volume":"90","author":"Baan","year":"2007"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0231|cit231","first-page":"1","article-title":"Primary end-points for prophylactic HPV vaccine trials","volume-title":"IARC Working Group Reports","volume":"7","author":"IARC HPV Working Group","year":"2013"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/oxfordjournals.jncimonographs.a003487","article-title":"Chapter 12: Human papillomavirus technologies","volume":"31","author":"Iftner","year":"2003","journal-title":"Journal of National Cancer Institute Monographs"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0233|cit233","unstructured":"Initiative for Vaccine Research of the Department of Immunization VaB Human Papillomavirus (HPV) Vaccine Background Paper World Health Organization (WHO) 2009 1 249"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2303.2008.00623.x","article-title":"European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1","volume":"19","author":"Jordan","year":"2008","journal-title":"Cytopathology"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2303.2008.00636.x","article-title":"European guidelines for management of abnormal cervical cytology, Part 2","volume":"20","author":"Jordan","year":"2009","journal-title":"Cytopathology"},{"issue":"8","key":"10.1002\/14651858.CD009069.pub3-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women","volume":"372","author":"Joura","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1056\/NEJMct0806938","article-title":"HPV vaccination for the prevention of cervical intraepithelial neoplasia","volume":"361","author":"Kahn","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1525-1438.2007.01123.x","article-title":"Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects","volume":"18","author":"Kang","year":"2008","journal-title":"International Journal of Gynecological Cancer"},{"issue":"11","key":"10.1002\/14651858.CD009069.pub3-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1038\/bjc.2014.198","article-title":"Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16\/18 and closely related HPV types","volume":"110","author":"Kavanagh","year":"2014","journal-title":"British Journal of Cancer"},{"issue":"12","key":"10.1002\/14651858.CD009069.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(17)30468-1","article-title":"Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study","volume":"17","author":"Kavanagh","year":"2017","journal-title":"Lancet Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD009069.pub3-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3346\/jkms.2010.25.8.1197","article-title":"Vaccination with a human papillomavirus (HPV)-16\/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years","volume":"25","author":"Kim","year":"2010","journal-title":"Journal of Korean Medical Science"},{"issue":"2","key":"10.1002\/14651858.CD009069.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3802\/jgo.2011.22.2.67","article-title":"Human papillomavirus 16\/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women","volume":"22","author":"Kim","year":"2011","journal-title":"Journal of Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/IGC.0b013e3181d373a5","article-title":"Efficacy of human papillomavirus 16\/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial","volume":"20","author":"Konno","year":"2010","journal-title":"International Journal of Gynecological Cancer"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/IGC.0b013e3181da2128","article-title":"Efficacy of human papillomavirus type 16\/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial","volume":"20","author":"Konno","year":"2010","journal-title":"International Journal of Gynecological Cancer"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.4161\/hv.28712","article-title":"Efficacy of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women","volume":"10","author":"Konno","year":"2014","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009069.pub3-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.vaccine.2006.06.014","article-title":"Chapter 13: Current findings from prophylactic HPV vaccine trials","volume":"24","author":"Koutsky","year":"2006","journal-title":"Vaccine"},{"issue":"19","key":"10.1002\/14651858.CD009069.pub3-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"dju436","DOI":"10.1093\/jnci\/dju436","article-title":"The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents","volume":"107","author":"Kreimer","year":"2015","journal-title":"Journal of the National Cancer Institute"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/aje\/kwu168","article-title":"Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates","volume":"180","author":"Kuhs","year":"2014","journal-title":"American Journal of Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD009069.pub3-BIB0251|cit251","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012847","article-title":"Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease","author":"Kyrgiou","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"0264-410X (Prin","key":"10.1002\/14651858.CD009069.pub3-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.vaccine.2006.06.015","article-title":"Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6\/11 disease","volume":"24","author":"Lacey","year":"2006","journal-title":"Vaccine"},{"issue":"9790","key":"10.1002\/14651858.CD009069.pub3-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0140-6736(11)60678-8","article-title":"Addressing the vaccine confidence gap","volume":"378","author":"Larson","year":"2011","journal-title":"Lancet"},{"issue":"0956-4624 (Prin","key":"10.1002\/14651858.CD009069.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1258\/095646206778145550","article-title":"Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing","volume":"17","author":"Lehtinen","year":"2006","journal-title":"International Journal of STD & AIDS"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 ASO4-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncology"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrclinonc.2013.84","article-title":"Clinical trials of human papillomavirus vaccines and beyond","volume":"10","author":"Lehtinen","year":"2013","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/jnci\/djt032","article-title":"Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study","volume":"105","author":"Leval","year":"2013","journal-title":"Journal of the National Cancer Institute"},{"issue":"0300-5283 (Prin","key":"10.1002\/14651858.CD009069.pub3-BIB0258|cit258","first-page":"2","article-title":"Immunogenicity and safety of the AS04-adjuvanted human papillomavirus-16\/18 cervical cancer vaccine in Malaysian women aged 18-35 years: a randomized controlled trial","volume":"69","author":"Lim","year":"2014","journal-title":"Medical Journal of Malaysia"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/AOG.0000000000002191","article-title":"Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy","volume":"130","author":"Lipkind","year":"2017","journal-title":"Obstetrics and Gynecology"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/21645515.2015.1012010","article-title":"Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine","volume":"11","author":"Luxembourg","year":"2015","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial","volume":"107","author":"Mao","year":"2006","journal-title":"Obstetrics and Gynecology"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/jit192","article-title":"Reduction in in human papillomavirus (HPV) prevalence among young women following HPVvaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010","volume":"208","author":"Markowitz","year":"2013","journal-title":"Journal of Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD009069.pub3-BIB0263|cit263","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001318.pub3","article-title":"Surgery for cervical intraepithelial neoplasia","author":"Martin-Hirsch","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncology"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/IGC.0b013e3181a3d100","article-title":"Efficacy of human papillomavirus vaccines: a systematic quantitative review","volume":"19","author":"Medeiros","year":"2009","journal-title":"International Journal of Gynecological Cancer"},{"issue":"1879-1972 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jadohealth.2010.02.006","article-title":"Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls","volume":"46","author":"Medina","year":"2010","journal-title":"Journal of Adolescent Health"},{"issue":"4","key":"10.1002\/14651858.CD009069.pub3-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/CEJ.0000000000000067","article-title":"Early effects of human papillomavirus vaccination in Belgium","volume":"24","author":"Merckx","year":"2015","journal-title":"European Journal of Cancer Prevention"},{"issue":"9","key":"10.1002\/14651858.CD009069.pub3-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"e0162520","DOI":"10.1371\/journal.pone.0162520","article-title":"Pre-vaccination care-seeking in females reporting severe adverse reactions to HPV vaccine. A registry based case-control study","volume":"11","author":"Molbak","year":"2016","journal-title":"PLOS One"},{"issue":"6","key":"10.1002\/14651858.CD009069.pub3-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/21645515.2015.1008877","article-title":"Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa","volume":"11","author":"Mugo","year":"2015","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen? The international perspective","volume":"111","author":"Munoz","year":"2004","journal-title":"International Journal of Cancer"},{"issue":"9679","key":"10.1002\/14651858.CD009069.pub3-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial","volume":"373","author":"Munoz","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"Journal of the National Cancer Institute"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.vaccine.2015.10.006","article-title":"Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011","volume":"34","author":"Naleway","year":"2016","journal-title":"Vaccine"},{"issue":"8","key":"10.1002\/14651858.CD009069.pub3-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination","volume":"10","author":"Naud","year":"2014","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"1024-2708 (Prin","key":"10.1002\/14651858.CD009069.pub3-BIB0275|cit275","first-page":"171","article-title":"Human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong","volume":"16","author":"Ngan","year":"2010","journal-title":"Hong Kong Medical Journal"},{"issue":"23","key":"10.1002\/14651858.CD009069.pub3-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.vaccine.2013.12.037","article-title":"Systematic review of human papillomavirus vaccine coadministration","volume":"32","author":"Noronha","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4161\/hv.26292","article-title":"Guillain-Barr\u00e9 syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States","volume":"10","author":"Ojha","year":"2014","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"2","key":"10.1002\/14651858.CD009069.pub3-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00004347-199304000-00018","article-title":"Natural history of cervical intraepithelial neoplasia: a critical review","volume":"12","author":"Ostor","year":"1993","journal-title":"International Journal of Gynegological Pathology"},{"issue":"9580","key":"10.1002\/14651858.CD009069.pub3-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"0264-410X, 5","key":"10.1002\/14651858.CD009069.pub3-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.vaccine.2004.07.046","article-title":"Efficacy and other milestones for human papillomavirus vaccine introduction","volume":"23","author":"Pagliusi","year":"2004","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"h4358","DOI":"10.1136\/bmj.h4358","article-title":"Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial","volume":"351","author":"Panagiotou","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jadohealth.2011.10.009","article-title":"Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16\/18AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls","volume":"50","author":"Pedersen","year":"2012","journal-title":"Journal of Adolescent Health"},{"issue":"9","key":"10.1002\/14651858.CD009069.pub3-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/bjc.2014.479","article-title":"Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland","volume":"111","author":"Pollock","year":"2014","journal-title":"British Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1503\/cmaj.070948","article-title":"Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials","volume":"177","author":"Rambout","year":"2007","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0286|cit286","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0287|cit287","first-page":"301","article-title":"Cervical intraepithelial neoplasia","volume":"8","author":"Richart","year":"1973","journal-title":"Pathology Annual"},{"issue":"9706","key":"10.1002\/14651858.CD009069.pub3-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years","volume":"374","author":"Romanowski","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD009069.pub3-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4161\/hv.7.2.13690","article-title":"Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines","volume":"7","author":"Romanowski","year":"2011","journal-title":"Human Vaccines"},{"issue":"9916","key":"10.1002\/14651858.CD009069.pub3-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"issue":"41","key":"10.1002\/14651858.CD009069.pub3-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1016\/j.vaccine.2009.07.027","article-title":"Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine","volume":"27","author":"Rowhani-Rahbar","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1002\/14651858.CD009069.pub3-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"djx158","DOI":"10.1093\/jnci\/djx158","article-title":"Durability of protection afforded by fewer doses of the HPV16\/18 vaccine: The CVT Trial","volume":"110","author":"Safaeian","year":"2018","journal-title":"Journal of the National Cancer Institute"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2016","journal-title":"Lancet Oncology"},{"issue":"2","key":"10.1002\/14651858.CD009069.pub3-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jama.2014.2198","article-title":"Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism","volume":"312","author":"Scheller","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.2014.16946","article-title":"Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system","volume":"313","author":"Scheller","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.virol.2005.04.002","article-title":"The carcinogenicity of human papillomavirus types reflects viral evolution","volume":"337","author":"Schiffman","year":"2005","journal-title":"Virology"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0297|cit297","doi-asserted-by":"crossref","unstructured":"Schiffman M Clifford G Buonaguro FM Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline Infectious Agents and Cancer 2009 1 8","DOI":"10.1186\/1750-9378-4-8"},{"issue":"2","key":"10.1002\/14651858.CD009069.pub3-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1086\/599988","article-title":"Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials","volume":"200","author":"Schiller","year":"2009","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30 Suppl 5","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"issue":"1873-2518","key":"10.1002\/14651858.CD009069.pub3-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"9276","DOI":"10.1016\/j.vaccine.2011.08.037","article-title":"Co-administration of human papillomavirus-16\/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls","volume":"29","author":"Schmeink","year":"2011","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0301|cit301","first-page":"1","article-title":"Cervical cancer. The potential role of human papillomavirus (HPV)-specific vaccines in prevention and treatment","volume":"2","author":"Schneider","year":"2003","journal-title":"American Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD009069.pub3-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jadohealth.2011.11.004","article-title":"Four-year follow-up of the immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years","volume":"50","author":"Schwarz","year":"2012","journal-title":"Journal of Adolescent Health"},{"issue":"42","key":"10.1002\/14651858.CD009069.pub3-BIB0303|cit303","first-page":"148","article-title":"Meta-analysis regression","volume":"7","author":"Sharp","year":"1998","journal-title":"Statistics Technical Bulletin"},{"issue":"9961","key":"10.1002\/14651858.CD009069.pub3-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(14)60920-X","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"384","author":"Skinner","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pvr.2017.03.001","article-title":"Incidence rates of Guillain-Barr\u00e9\u201a (GBS), chronic fatigue\/systemic exertion intolerance disease (CFS\/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002-2012","volume":"3","author":"Skufca","year":"2017","journal-title":"Papillomavirus Research"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0307|cit307","doi-asserted-by":"crossref","unstructured":"Smith HO Tiffany MF Qualls CR Key CR The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study Gynecologic Oncology 2000 97 105","DOI":"10.1006\/gyno.2000.5826"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","article-title":"The 2001 Bethesda System: terminology for reporting results of cervical cytology","volume":"287","author":"Solomon","year":"2002","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD009069.pub3-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/infdis\/jis619","article-title":"Safety and immunogenicity of human papillomavirus-16\/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-seronegative African girls and young women","volume":"207","author":"Sow","year":"2013","journal-title":"Journal of Infectious Diseases"},{"issue":"1052-9276 (Prin","key":"10.1002\/14651858.CD009069.pub3-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/rmv.498","article-title":"Human papillomavirus vaccines","volume":"16","author":"Stanley","year":"2006","journal-title":"Reviews in Medical Virology"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"F83","DOI":"10.1016\/j.vaccine.2012.04.106","article-title":"Human papillomavirus vaccines - immune responses","volume":"30 (Suppl 5)","author":"Stanley","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"10.1002\/14651858.CD009069.pub3-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1586\/14760584.2014.935767","article-title":"Alternative dosage schedules with HPV virus-like particle vaccines","volume":"13","author":"Stanley","year":"2014","journal-title":"Expert Review of Vaccines"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.puhe.2015.11.020","article-title":"Response letter regarding the letter to the editors by Butt et al. Does it matter Discounting and its role in the cost-effectiveness of preventative interventions. The case of HPV vaccination","volume":"132","author":"Starkie Camejo","year":"2016","journal-title":"Public Health"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1517\/14712591003601944","article-title":"HPV vaccine: Cervarix","volume":"10","author":"Szarewski","year":"2010","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/ijc.26362","article-title":"Efficacy of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16\/18","volume":"131","author":"Szarewski","year":"2011","journal-title":"Internaitonal Journal of Cancer"},{"issue":"11","key":"10.1002\/14651858.CD009069.pub3-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/infdis\/jis590","article-title":"Fall in human papillomavirus prevalence following a national vaccination program","volume":"206","author":"Tabrizi","year":"2012","journal-title":"Journal of Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD009069.pub3-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study","volume":"14","author":"Tabrizi","year":"2014","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0318|cit318","doi-asserted-by":"crossref","unstructured":"Taylor S Ryser M Mihalyi A van Effelterre T Response letter regarding the letter to the editors by Brown et al Human Vaccinnes and Immunotherapeutics 2016 1943 6","DOI":"10.1080\/21645515.2016.1151598"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 ASO4-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years","volume":"374","author":"The GlaxoSmithKline Vaccine HPV-007 Study Group","year":"2009","journal-title":"Lancet"},{"issue":"20","key":"10.1002\/14651858.CD009069.pub3-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V","article-title":"Explaining heterogeneity in meta-analysis: a comparison of methods","volume":"18","author":"Thompson","year":"1999","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0321|cit321","volume-title":"Human Papillomavirus Laboratory Manual","author":"Unger","year":"2010"},{"issue":"29","key":"10.1002\/14651858.CD009069.pub3-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1016\/j.vaccine.2014.03.040","article-title":"Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials","volume":"32","author":"Damme","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD009069.pub3-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1542\/peds.2014-3745","article-title":"Immunogenicity and Safety of a 9-Valent HPV Vaccine","volume":"136","author":"Damme","year":"2015","journal-title":"Pediatrics"},{"issue":"0264-410X (Prin","key":"10.1002\/14651858.CD009069.pub3-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.1016\/j.vaccine.2008.09.049","article-title":"Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines","volume":"26","author":"Verstraeten","year":"2008","journal-title":"Vaccine"},{"issue":"9","key":"10.1002\/14651858.CD009069.pub3-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/INF.0000000000000773","article-title":"A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil(R) in 9-15-year-old girls","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"9","key":"10.1002\/14651858.CD009069.pub3-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/INF.0000000000000793","article-title":"An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015","volume":"34","author":"Vichnin","year":"2015","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"5","key":"10.1002\/14651858.CD009069.pub3-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncology"},{"issue":"27","key":"10.1002\/14651858.CD009069.pub3-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"issue":"11","key":"10.1002\/14651858.CD009069.pub3-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"c712","DOI":"10.1136\/bmj.c712","article-title":"Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials","volume":"340","author":"Wacholder","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"16 (10)","author":"Wheeler","year":"2016","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0332|cit332","unstructured":"Initiative for Vaccine Research of the Department of Immunization Vaccines and Biologicals (WHO) Human Papillomavirus (HPV) Vaccine Background Paper World Health Organization (WHO) 2009 1 249"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0333|cit333","unstructured":"WHO Global Advisory Committee on Vaccine Safety Statement on the continued safety of HPV vaccination http:\/\/www.who.int\/vaccine_safety\/committee\/topics\/hpv\/GACVS_Statement_HPV_12_Mar_2014.pdf 2014"},{"issue":"3","key":"10.1002\/14651858.CD009069.pub3-BIB0334|cit334","first-page":"26","article-title":"Safety of HPV vaccines (from meeting of 2-3 December, 2015)","volume":"91","author":"WHO","year":"2016","journal-title":"Weekly Epidemiological Record"},{"key":"10.1002\/14651858.CD009069.pub3-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/aje\/kwf180","article-title":"Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students","volume":"157","author":"Winer","year":"2003","journal-title":"Journal of Epidemiology"},{"issue":"0022-1899 (Prin","key":"10.1002\/14651858.CD009069.pub3-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1086\/524875","article-title":"Risk of female human papillomavirus acquisition associated with first male sex partner","volume":"197","author":"Winer","year":"2008","journal-title":"Journal of Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD009069.pub3-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/cas.12106","article-title":"Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years","volume":"104","author":"Yoshikawa","year":"2013","journal-title":"Cancer Science"},{"issue":"1097-0215 (Elec","key":"10.1002\/14651858.CD009069.pub3-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/ijc.28897","article-title":"Efficacy, immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial","volume":"135","author":"Zhu","year":"2014","journal-title":"International Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD009069.pub3-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.4161\/hv.28702","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years","volume":"10","author":"Zhu","year":"2014","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"4","key":"10.1002\/14651858.CD009069.pub3-BIB0340|cit340","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009069","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","author":"Arbyn","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD009069.pub3-BIB0341|cit341","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009069.pub2","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","author":"Arbyn","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009069.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T09:34:02Z","timestamp":1758015242000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009069.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,5,9]]},"references-count":341,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009069.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,9]]}}}